CoChat

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Open access
Mota, Jose Mauricio, Collier, Katharine Ann, Barros Costa, Ricardo Lima, Taxter, Timothy, Kalyan, Aparna, Leite, Caio A., Chae, Young Kwang, Giles, Francis J., Carneiro, Benedito A. · 2017 · Oncotarget
Cited by 69

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Jose Mauricio Mota 1 , Katharine Ann Collier 3 , Ricardo Lima Barros Costa 2 , Timothy Taxter 2 , Aparna Kalyan 2 , Caio A. Leite 4 , Young Kwang Chae 2 , Francis J. Giles 2 and Benedito A. Carneiro 2 1 Instituto do Câncer do Estado de São Paulo, Division of Oncology, Universidade de São Paulo, São Paulo, Brazil 2 Developmental Therapeutics Program, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 3 Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 4 Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil Correspondence to: Benedito A. Carneiro, email: // Keywords : heregulins, HER3, HER4, cancer, developmental therapeutics Received : March 19, 2017 Accepted : April 17, 2017 Published : June 13, 2017 Abstract Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and trigger downstream signaling that leads to tumor progression and resistance to targeted therapies. Increased expression of HRGs has been associated with worse clinical prognosis; therefore, attempts to block HRG-dependent tumor growth have been pursued. This manuscript summarizes the function and signaling of HRGs and review the preclinical evidence of its involvement in carcinogenesis, prognosis, and treatment resistance in several malignancies such as colorectal cancer, non-small cell lung cancer, ovarian cancer, and breast cancer. Agents in preclinical development and clinical trials of novel therapeutics targeting HRG-dependent signaling are also discussed, including anti-HER3 and -HER4 antibodies, anti-metalloproteinase agents, and HRG fusion proteins. Although several trials have indicated an acceptable safety profile, translating preclinical findings into clinical practice remains a challenge in this field, possibly due to the complexity of downstream signaling and patterns of HRG, HER3 and HER4 expression in different cancer subtypes. Improving patient selection through biomarkers and understanding the resistance mechanisms may translate into significant clinical benefits in the near future.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.18467

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Mota, J. M., Collier, K. A., Barros Costa, R. L., Taxter, T., Kalyan, A., Leite, C. A., Chae, Y. K., Giles, F. J., & Carneiro, B. A.
Venue
Oncotarget
Published
2017-06-13
Volume
8
Issue
51
Pages
89284-89306
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2625993296
Cited by
69
References
7
FWCI
2.80
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.